Reporting cases of misconduct in the context of federal science funding can be a daunting task. But mechanisms to support whistleblowers do exist.

As the world around us seems increasingly volatile, protecting and respecting the integrity of research and evidence becomes more important than ever.

While some academics have called for compensation for assessing other scientists’ work, publishers haven’t warmed to the idea.

Sapan Desai has inactivated his license in Illinois, where multiple malpractice lawsuits against him are pending, and obtained a new one in Ohio.

The changes, which affect the declarations authors have to sign and the peer-review process, have received a mixed response from the scientific community.

Pier Paolo Pandolfi left Harvard University last year following allegations of sexual harassment, and has since been accused of research misconduct.

Fast science—with all its warts—is making unprecedented progress in the fight against COVID-19.

The company behind a now-discredited study on hydroxychloroquine also posted a report that has been cited by Latin American governments recommending ivermectin as a possible coronavirus treatment. Clinicians there say the effects have been extremely damaging.

Our handbook on best practices for quality assurance in biomedicine can help funding agencies shore up research integrity—which is especially needed at a time when mistakes can have outsize effects.